O
One Biosciences
Operating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases
About One Biosciences
One Biosciences operates in the biotechnology sector, focusing on the development of RNA-based therapies aimed at precision medicine. The company leverages advanced RNA technologies to create personalized healthcare solutions, targeting specific genetic profiles to treat various diseases. One Biosciences primarily serves healthcare providers, pharmaceutical companies, and research institutions. The company operates in the global biotechnology market, which is characterized by rapid innovation and high growth potential. Its business model revolves around research and development, clinical trials, and eventual commercialization of its RNA-based therapies. Revenue is generated through partnerships, licensing agreements, and sales of proprietary treatments. The company is led by a team of experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and finance, ensuring a strong foundation for growth and innovation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Paris, France
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 91.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Core AI, Precision Medicine, Spinout, Biotech and Pharma, AI Drug Discovery, biotech medtech and e-health
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jun 2026 | $0 | — | Capscion · Incuballiance Paris-Saclay | ↗ |
| SERIES A✓Equity / VC | Jul 2025 | $17M | $66M | Galion.exe · Adamed Technology · Redmile Group · Polytechnique Ventures | ↗ |
Growth signals
Latest recorded traffic for One Biosciences is 620 monthly website visits, up 29.2% over the last three months. One Biosciences's team grew 19.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Capscion
Incuballiance Paris-Saclay
Series A10 investors entered at this stage
HOME BIOSCIENCES
Institut Curie
Redmile Group
Blast. Club
Galion.exe- ATAdamed Technology
Polytechnique Ventures
Kima Ventures
Sofinnova Partners
Invus
Other known investors4 additional known investors
CNRS Innovation
French National Centre for Scientific Research - CNRS
PSL University
Agoranov
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about One Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See One Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.